Amedeo Smart

Free Medical Literature Service


 

Amedeo

Alzheimer's Disease

  Free Subscription

Articles published in
Science
    March 2024
  1. PILLER C
    'Damning' FDA inspection report undermines Alzheimer's drug.
    Science. 2024;383:1165-1166.
    >> Share

    December 2023
  2. GOLDE TE, Levey AI
    Immunotherapies for Alzheimer's disease.
    Science. 2023;382:1242-1244.
    >> Share

    November 2023
  3. PILLER C
    Brain games?
    Science. 2023;382:754-759.
    >> Share

    October 2023
  4. PILLER C
    Probe of Alzheimer's studies finds 'egregious misconduct'.
    Science. 2023;382:251-252.
    >> Share

    September 2023
  5. BALUSU S, Horre K, Thrupp N, Craessaerts K, et al
    MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer's disease.
    Science. 2023;381:1176-1182.
    >> Share

  6. SIRKIS DW, Yokoyama JS
    Role for cell death pathway in Alzheimer's disease.
    Science. 2023;381:1156-1157.
    >> Share

  7. AGUZZI A, Kampmann M
    Neurodegeneration enters the era of functional genomics.
    Science. 2023;381:eadk5693.
    >> Share

    August 2023
  8. COUZIN-FRANKEL J
    Side effects loom over Alzheimer's drugs.
    Science. 2023;381:466-467.
    >> Share

    July 2023
  9. ZHANG ZY, Harischandra DS, Wang R, Ghaisas S, et al
    TRIM11 protects against tauopathies and is down-regulated in Alzheimer's disease.
    Science. 2023;381:eadd6696.
    >> Share

    May 2023
  10. TRAVIS J
    Latest Alzheimer's antibody is 'not a miracle drug'.
    Science. 2023;380:571.
    >> Share

    April 2023
  11. PILLER C
    Report on trial death stokes Alzheimer's drug fears.
    Science. 2023;380:122-123.
    >> Share

  12. COUZIN-FRANKEL J
    Promising Alzheimer's therapies shrink brains.
    Science. 2023;380:19.
    >> Share

    January 2023
  13. COUZIN-FRANKEL J
    Alzheimer's drug approval gets a mixed reception.
    Science. 2023;379:126-127.
    >> Share

    December 2022
  14. COUZIN-FRANKEL J, Piller C
    Alzheimer's drug stirs excitement-and concerns.
    Science. 2022;378:1030-1031.
    >> Share

    November 2022
  15. PILLER C
    Whistleblower finds possible misconduct in his own papers.
    Science. 2022;378:694-695.
    >> Share

  16. ENDO F, Kasai A, Soto JS, Yu X, et al
    Molecular basis of astrocyte diversity and morphology across the CNS in health and disease.
    Science. 2022;378:eadc9020.
    >> Share

    September 2022
  17. HOFFMANN HM
    Boosting cognition with a hormone.
    Science. 2022;377:1042-1043.
    >> Share

    August 2022
  18. ASHE KH
    Alzheimer's target still viable but untested.
    Science. 2022;377:935.
    >> Share

  19. SELKOE D, Cummings J
    News story miscasts Alzheimer's science.
    Science. 2022;377:934-935.
    >> Share

  20. COOPER YA, Teyssier N, Drager NM, Guo Q, et al
    Functional regulatory variants implicate distinct transcriptional networks in dementia.
    Science. 2022;377:eabi8654.
    >> Share

    July 2022
  21. PILLER C
    Research backing experimental Alzheimer's drug was first target of suspicion.
    Science. 2022;377:363.
    >> Share

  22. PILLER C
    Research backing experimental Alzheimer's drug was first target of suspicion.
    Science. 2022;377:363.
    >> Share

  23. PILLER C
    Blots on a field?
    Science. 2022;377:358-363.
    >> Share

  24. ZHOU X, Sumrow L, Tashiro K, Sutherland L, et al
    Mutations linked to neurological disease enhance self-association of low-complexity protein sequences.
    Science. 2022;377:eabn5582.
    >> Share

    January 2022
  25. YANG Y, Arseni D, Zhang W, Huang M, et al
    Cryo-EM structures of amyloid-beta 42 filaments from human brains.
    Science. 2022;375:167-172.
    >> Share

    December 2021
  26. LESLIE M
    Blood condition may guard against Alzheimer's.
    Science. 2021;374:1425.
    >> Share

    October 2021
  27. SELKOE DJ
    Alzheimer's drugs: Does reducing amyloid work?-Response.
    Science. 2021;374:545-546.
    >> Share

  28. THAMBISETTY M, Howard R, Glymour MM, Schneider LS, et al
    Alzheimer's drugs: Does reducing amyloid work?
    Science. 2021;374:544-545.
    >> Share

  29. SPIRES-JONES T
    Toward a holistic model of Alzheimer'sHow Not to Study a Disease: The Story of Alzheimer's Karl Herrup MIT Press, 2021. 272 pp.
    Science. 2021;374:267.
    >> Share

    August 2021
  30. BLENNOW K
    Phenotyping Alzheimer's disease with blood tests.
    Science. 2021;373:626-628.
    >> Share

  31. SELKOE DJ
    Treatments for Alzheimer's disease emerge.
    Science. 2021;373:624-626.
    >> Share

    July 2021
  32. SERVICK K
    Alzheimer's drug approval spotlights blood tests.
    Science. 2021;373:373-374.
    >> Share

    June 2021
  33. SERVICK K
    Alzheimer's drug approved despite murky results.
    Science. 2021;372:1141.
    >> Share

    December 2020
  34. NAKAMURA T, Oh CK, Liao L, Zhang X, et al
    Noncanonical transnitrosylation network contributes to synapse loss in Alzheimer's disease.
    Science. 2020 Dec 3. pii: science.aaw0843. doi: 10.1126/science.aaw0843.
    >> Share

    November 2020
  35. DARWICH NF, Phan JM, Kim B, Suh E, et al
    Autosomal dominant VCP hypomorph mutation impairs disaggregation of PHF-tau.
    Science. 2020;370.
    >> Share

    October 2020
  36. BARTELS T, De Schepper S, Hong S
    Microglia modulate neurodegeneration in Alzheimer's and Parkinson's diseases.
    Science. 2020;370:66-69.
    >> Share

  37. SIERKSMA A, Escott-Price V, De Strooper B
    Translating genetic risk of Alzheimer's disease into mechanistic insight and drug targets.
    Science. 2020;370:61-66.
    >> Share

  38. NEDERGAARD M, Goldman SA
    Glymphatic failure as a final common pathway to dementia.
    Science. 2020;370:50-56.
    >> Share

    August 2020
  39. SUZUKI K, Elegheert J, Song I, Sasakura H, et al
    A synthetic synaptic organizer protein restores glutamatergic neuronal circuits.
    Science. 2020;369.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016